113 related articles for article (PubMed ID: 17357513)
1. [The expression of tumor necrosis factor related apoptosis induce ligand in human laryngeal squamous cell carcinoma].
Yao H; Ji W; Guan C; Liu B
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Dec; 20(24):1105-8. PubMed ID: 17357513
[TBL] [Abstract][Full Text] [Related]
2. Association between laryngeal squamous cell carcinoma and polymorphisms in tumor necrosis factor related apoptosis induce ligand (TRAIL), TRAIL receptor and sTRAIL levels.
Verim A; Turan S; Farooqi AA; Kahraman OT; Tepe-Karaca C; Yildiz Y; Naiboglu B; Ozkan NE; Ergen A; Isitmangil GA; Yaylim I
Asian Pac J Cancer Prev; 2014; 15(24):10697-703. PubMed ID: 25605161
[TBL] [Abstract][Full Text] [Related]
3. Hypermethylation of DcR1, DcR2, DR4, DR5 gene promoters and clinical significance in tongue carcinoma.
Zhou Y; Zheng S; Luo Q; Huang X; Zhou Y; Li Z
Am J Otolaryngol; 2019; 40(6):102258. PubMed ID: 31399243
[TBL] [Abstract][Full Text] [Related]
4. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.
Vigneswaran N; Baucum DC; Wu J; Lou Y; Bouquot J; Muller S; Zacharias W
BMC Cancer; 2007 Jun; 7():108. PubMed ID: 17592646
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer.
Yoldas B; Ozer C; Ozen O; Canpolat T; Dogan I; Griffith TS; Sanlioglu S; Ozluoglu LN
Head Neck; 2011 Sep; 33(9):1278-84. PubMed ID: 21837697
[TBL] [Abstract][Full Text] [Related]
6. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.
van Noesel MM; van Bezouw S; Salomons GS; Voûte PA; Pieters R; Baylin SB; Herman JG; Versteeg R
Cancer Res; 2002 Apr; 62(7):2157-61. PubMed ID: 11929838
[TBL] [Abstract][Full Text] [Related]
8. Membrane expression of TRAIL receptors DR4, DR5, DcR1 and DcR2 in the normal endometrium, atypical endometrial hyperplasia and endometrioid adenocarcinoma: a tissue microarray study.
Gottwald L; Piekarski J; Kubiak R; Szwalski J; Pasz-Walczak G; Sęk P; Spych M; Suzin J; Tyliński W; Jeziorski A
Arch Gynecol Obstet; 2013 Oct; 288(4):889-99. PubMed ID: 23584885
[TBL] [Abstract][Full Text] [Related]
9. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
[TBL] [Abstract][Full Text] [Related]
10. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas.
Koornstra JJ; Kleibeuker JH; van Geelen CM; Rijcken FE; Hollema H; de Vries EG; de Jong S
J Pathol; 2003 Jul; 200(3):327-35. PubMed ID: 12845629
[TBL] [Abstract][Full Text] [Related]
11. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
12. Expression of tumor necrosis factor-related apoptosis-inducing ligand death receptors DR4 and DR5 in human nonmelanoma skin cancer.
Omran OM; Ata HS
Am J Dermatopathol; 2014 Sep; 36(9):710-7. PubMed ID: 24212133
[TBL] [Abstract][Full Text] [Related]
13. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
Gasparian ME; Chernyak BV; Dolgikh DA; Yagolovich AV; Popova EN; Sycheva AM; Moshkovskii SA; Kirpichnikov MP
Apoptosis; 2009 Jun; 14(6):778-87. PubMed ID: 19412666
[TBL] [Abstract][Full Text] [Related]
14. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
Spierings DC; de Vries EG; Timens W; Groen HJ; Boezen HM; de Jong S
Clin Cancer Res; 2003 Aug; 9(9):3397-405. PubMed ID: 12960128
[TBL] [Abstract][Full Text] [Related]
15. DR5 and DcR2 are expressed in human lumbar intervertebral discs.
Chen B; Ma B; Yang S; Xing X; Gu R; Hu Y
Spine (Phila Pa 1976); 2009 Sep; 34(19):E677-81. PubMed ID: 19730199
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
17. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
[TBL] [Abstract][Full Text] [Related]
18. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
Leithner K; Stacher E; Wurm R; Ploner F; Quehenberger F; Wohlkoenig C; Bálint Z; Polachova J; Olschewski A; Samonigg H; Popper HH; Olschewski H
Lung Cancer; 2009 Jul; 65(1):98-104. PubMed ID: 19081160
[TBL] [Abstract][Full Text] [Related]
19. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
Koyama S; Koike N; Adachi S
J Cancer Res Clin Oncol; 2002 Feb; 128(2):73-9. PubMed ID: 11862476
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
